Nektar Therapeutics/$NKTR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Ticker
$NKTR
Sector
Primary listing
Employees
61
Headquarters
Website
NKTR Metrics
BasicAdvanced
$2.1B
-
-$9.73
1.23
-
Price and volume
Market cap
$2.1B
Beta
1.23
52-week high
$77.00
52-week low
$7.99
Average daily volume
1.5M
Financial strength
Current ratio
4.974
Quick ratio
4.59
Long term debt to equity
142.948
Total debt to equity
165.763
Interest coverage (TTM)
-4.99%
Profitability
EBITDA (TTM)
-129.656
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-297.07%
Operating margin (TTM)
-236.77%
Effective tax rate (TTM)
0.08%
Revenue per employee (TTM)
$910,000
Management effectiveness
Return on assets (TTM)
-27.98%
Return on equity (TTM)
-217.94%
Valuation
Price to revenue (TTM)
22.057
Price to book
16.38
Price to tangible book (TTM)
16.32
Price to free cash flow (TTM)
-5.818
Free cash flow yield (TTM)
-17.19%
Free cash flow per share (TTM)
-12.411
Growth
Revenue change (TTM)
-43.89%
Earnings per share change (TTM)
12.14%
3-year revenue growth (CAGR)
-15.66%
10-year revenue growth (CAGR)
-13.32%
3-year earnings per share growth (CAGR)
-30.95%
10-year earnings per share growth (CAGR)
0.57%
NKTR News
AllArticlesVideos
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
Business Wire·1 hour ago
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
Newsfile Corp·20 hours ago
Law Offices of Frank R. Cruz Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
Business Wire·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nektar Therapeutics stock?
Nektar Therapeutics (NKTR) has a market cap of $2.1B as of March 17, 2026.
What is the P/E ratio for Nektar Therapeutics stock?
The price to earnings (P/E) ratio for Nektar Therapeutics (NKTR) stock is 0 as of March 17, 2026.
Does Nektar Therapeutics stock pay dividends?
No, Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders as of March 17, 2026.
When is the next Nektar Therapeutics dividend payment date?
Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders.
What is the beta indicator for Nektar Therapeutics?
Nektar Therapeutics (NKTR) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.